GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaccinex Inc (NAS:VCNX) » Definitions » ROC (Joel Greenblatt) %

Vaccinex (Vaccinex) ROC (Joel Greenblatt) % : -4,178.90% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Vaccinex ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vaccinex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4,178.90%.

The historical rank and industry rank for Vaccinex's ROC (Joel Greenblatt) % or its related term are showing as below:

VCNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5616.24   Med: -4942.98   Max: -1500.41
Current: -5020.08

During the past 8 years, Vaccinex's highest ROC (Joel Greenblatt) % was -1500.41%. The lowest was -5616.24%. And the median was -4942.98%.

VCNX's ROC (Joel Greenblatt) % is ranked worse than
87.2% of 1469 companies
in the Biotechnology industry
Industry Median: -336.59 vs VCNX: -5020.08

Vaccinex's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 1.30% per year.


Vaccinex ROC (Joel Greenblatt) % Historical Data

The historical data trend for Vaccinex's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaccinex ROC (Joel Greenblatt) % Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -5,319.37 -5,616.24 -5,051.76 -4,229.03 -5,179.03

Vaccinex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,740.70 -4,067.21 -6,396.38 -5,184.17 -4,178.90

Competitive Comparison of Vaccinex's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Vaccinex's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaccinex's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaccinex's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Vaccinex's ROC (Joel Greenblatt) % falls into.



Vaccinex ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.933 + 0 + 1.146) - (6.12 + 0 + 0)
=-4.041

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.961 + 0 + 0.853) - (3.281 + 0.063 + 2.351)
=-3.881

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Vaccinex for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.268/( ( (0.352 + max(-4.041, 0)) + (0.283 + max(-3.881, 0)) )/ 2 )
=-13.268/( ( 0.352 + 0.283 )/ 2 )
=-13.268/0.3175
=-4,178.90 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vaccinex  (NAS:VCNX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Vaccinex ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Vaccinex's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaccinex (Vaccinex) Business Description

Traded in Other Exchanges
N/A
Address
1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Executives
Van Strydonck, Gerald E. director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Maurice Zauderer director, 10 percent owner, officer: President and CEO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Albert Friedberg director, 10 percent owner
Jacob B. Frieberg director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Elizabeth E. Evans officer: Chief Operating Officer C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Robert Scala officer: Chief Commercial Officer 1895 MT HOPE AVENUE, ROCHESTER NY 14620
Chrystyna Bedrij Stecyk director 1895 MT. HOPE AVENUE, ROCHESTER NY 14620
Vaccinex, Inc. director 1895 MOUNT HOPE AVE, ROCHESTER NY 14620
Jeff Goater director C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Alejandro M. Berlin director 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
John E. Leonard officer: SVP, Development 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Ernest S. Smith officer: SVP, Research & CSO 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620
Raymond E. Watkins officer: SVP & Chief Operating Officer 1895 MOUNT HOPE AVENUE, ROCHESTER NY 14620